Human prion diseases are a heterogeneous group of fatal neurodegenerative disorders, characterized by the deposition of the partially protease-resistant prion protein (PrP res ), astrocytosis, neuronal loss and spongiform change in the brain. Among inherited forms that represent 15% of patients, different phenotypes have been described depending on the variations detected at different positions within the prion protein gene. Here, we report a new mechanism governing the phenotypic variability of inherited prion diseases. First, we observed that the substitution at residue 211 with either Gln or Asp leads to distinct disorders at the clinical, neuropathological and biochemical levels (Creutzfeldt -Jakob disease or GerstmannSträ ussler -Scheinker syndrome with abundant amyloid plaques and tau neurofibrillar pathology). Then, using molecular dynamics simulations and biophysical characterization of mutant proteins and an in vitro model of PrP conversion, we found evidence that each substitution impacts differently the stability of PrP and its propensity to produce different protease resistant fragments that may contribute to the phenotypical switch. Thus, subtle differences in the PrP primary structure and stability are sufficient to control amyloid
INTRODUCTION
The specific biochemical hallmark of prion disease is the accumulation of an abnormal partially protease-resistant isoform (PrP res ) of the host-encoded cellular prion protein (PrP C ). PrP C is encoded by the PRNP gene (MIM#176640), mapped to chromosome 20p12pter in humans (1) . According to the 'protein only' hypothesis, the mechanism for prion propagation involves the conversion of PrP C into PrP res (2 -4) . Prion diseases occur in acquired, inherited and sporadic forms. Different genetic forms have been reported in humans depending on the variations within PRNP: (i) genetic Creutzfeldt-Jakob disease (CJD), a rapidly progressive dementia associated with myoclonus and other neurological symptoms; (ii) GerstmannSträussler -Scheinker syndrome (GSS; MIM# 137440), usually an inaugural ataxia of slow progression with a late dementia; (iii) fatal familial insomnia (FFI), a refractory insomnia with hallucinations and dysautonomia. The neuropathology of patients with genetic CJD shows typically spongiform change and gliosis in cortical areas and the striatum. GSS is defined by multicentric amyloid plaques of PrP. In FFI, a severe involvement of the thalamus is observed. All these disorders show an autosomal dominant transmission. To date, the phenotype observed in inherited prion diseases is governed by two different mechanisms. First, the presence of a specific mutation (either point mutation or insertion in the N-terminal part of PrP) is associated with either CJD (e.g. in the E200K mutation), GSS (e.g. in the P102L mutation) or FFI, observed in patients with the D178N mutation (5 -9) . Second, in the D178N mutation, the phenotype is driven by a methionine -valine polymorphism at codon 129 of PRNP. The mutant allele with a methionine at codon 129 is associated with FFI, while a mutant allele with a valine is associated with CJD (10) . Here, we report a novel mechanism governing the phenotypic expression of genetic prion diseases. We observed that substitutions at codon 211 of PRNP drive a phenotypical switch between two distinct inherited prion diseases (CJD versus GSS syndrome with tau pathology such as neurofibrillar tangles and neuritic plaques usually observed in Alzheimer's disease). Mutations at position 211 affected differently PrP stability as shown by molecular dynamics (MD) and the differential calorimetric experiments by using different recombinant forms of the PrP mutant. Moreover, the exploration of the oligomerization pattern of E211Q and E211D indicated a distinct oligomerization pathway. Altogether, these distinct physico-chemical properties probably account for the different PrP res fragments found in the brain of 211-associated CJD and GSS patients that exhibited distinct behaviors in an in vitro model of prion protein conversion. Our study strongly supports a conformational change, the prion protein misfolding, as a key event in prion-related pathological process including amyloid-triggered tau fibrillar pathology.
RESULTS
We identified a kindred showing a clinical phenotype (Supplementary Material, Table S1 ) including inaugural ataxia and secondary dementia with a long duration of the disease (3 years) suggesting an ataxic form of GSS. Direct sequencing of PRNP was performed in the propositus and a novel GSS-associated point mutation (NM_000311.3:c.633C.G; p.Glu211Asp) designated as the E211D mutation was identified. The patient was homozygous for valine at codon 129 and homozygous for glutamic acid at codon 219 of PRNP.
The neuropathological study showed typical features of GSS (Figs 1 and 2 ), including numerous multicentric amyloid plaques of PrP stained by 12F10 antibody and negative for A-beta amyloid immunostaining in the isocortical areas and cerebellum, in association with mild gliosis and spongiform change. In addition, there were abundant taupositive dystrophic neurites around PrP plaques and numerous tau-positive neurofibrillary tangles within neurons, as seen in some GSS kindred ( Fig. 2) (11) .
In addition, we identified also two patients with the mutation (NM_000311.3:c.631G.C; p.Glu211Gln) designated as the E211Q mutation (Supplementary Material, Table S1 ). Both were homozygous for methionine at codon 129. The clinical phenotype was different from that of the patient with the E211D mutation. In both patients, inaugural dementia was observed and the duration of the disease was shorter (6 and 8 months) when compared with the patient with the E211D mutation. The neuropathological examination in patients with the E211Q mutation showed neither multicentric plaques typical of GSS nor tau-positive lesions. As shown in Figure 1 , spongiform change and gliosis were observed in the striatum and the isocortex. PrP immunohistochemistry revealed very mild synaptic deposits especially in the cerebellar cortex. Amyloid plaques were not observed. The final diagnosis was genetic CJD in both patients.
PK-resistant prion protein was detected regardless of the substitution at codon 211 (Fig. 3) . In the patient with the E211Q mutation, a PrP res pattern with co-occurrence of the two main types usually found in sporadic CJD (i.e. PrP res types 1 and 2A) was detected using the 3F4 reference antibody, the 12B2 antibody that is specific for PrP res type 1 and the 1E4 antibody that has shown a higher sensitivity to detect PrP res type 2A when both types naturally co-exist, in agreement with the diagnosis of CJD ( Fig. 3C and D) (12) (13) (14) (15) . PrP res type 1 was the main species in all studied areas. In contrast, the patient with the E211D mutation showed a distinct pattern with a major low-molecular-weight fragment (Fig. 3A) . This 7-kDa fragment was detected using the 3F4 antibody that recognizes a central epitope (i.e. 109-112) within the human PrP sequence but not using the SAF60 antibody that recognizes a more C-terminal epitope (i.e. 157-161; Fig. 3B ). This result was consistent with previous studies that showed the accumulation of a Cterminal truncated PrP res fragment (roughly covering amino acids 80-150) in some other GSS kindreds (16, 17) and suggested that E211D and E211Q substitutions differently impact prion protein stability.
We then explored the effect of both mutations on PrP conformational dynamics using different biophysical approaches. To study first the overall fold of these mutants, we expressed and purified these two mutants and performed circular dichroism (CD). As shown in Figure 4A , the dichrogram of these mutants were indistinguishable from the alpha fold of wildtype (WT) human PrP, suggesting an identical secondary structure repartition. In order to determine whether E211D and E211Q substitutions affect the PrP unfolding pathway, we then performed differential scanning calorimetry (DSC; Fig. 4B ). In DSC thermogram of recombinant PrP, the second transition corresponds to the unfolding/depolymerization of PrP oligomers and both the melting point (T m ) and the surface of the second transition peak reflect the oligomerization propensity (18) . We observed that both E211Q and E211D increased the T m and surface of the second transition (Fig. 4B) , indicating an increase in aggregation propensity. To further explore the oligomerization pathway of E211Q and E211D, we used physico-chemical conditions which allowed us to obtain discrete oligomers (19) and measured their aggregation pattern by size exclusion chromatography (SEC). As shown in Figure 4C , compared with WT and E211Q, the propensity of E211D to form high-molecularweight oligomers was higher. This observation was in good agreement with the DSC themograms, which indicated (i) a native fold destabilization and (ii) a higher propensity to form oligomers.
To investigate the molecular mechanisms of the E211Q and E211D induced destabilization, we then studied the effect of both substitutions at codon 211 on PrP stability using extended MD simulations in explicit solvent at physiological temperature (310 K). We first focused on the local effects of the mutations (Fig. 5) . In the N-terminal helix H3, WT human PrP displays a highly populated salt-bridge between R208 and E211 (Fig. 5A ). In the case of the E211D mutation, the saltbridge between R208 and E211 was no longer strictly formed, and alternatively a newly promoted salt-bridge between R208 of helix H3 and E146 of helix H1 was frequently formed ( Fig. 5A -C) . In contrast, the E211Q mutation did not impact much the population of the 208 -211 interaction and did not stabilize the 146-208 contact, suggesting that E211Q PrP is characterized by local features mostly resembling WT. Large-scale motions were examined using several order parameters. While the root-mean-square fluctuation (RMSF) profiles of WT and E211Q/M129 PrP superposed very well (Fig. 6C ), both the E211D/M129 and E211D/V129 RMSF profiles deviated from WT with a peak in vicinity of and E211Q PrP that displayed a unique nuclear magnetic resonance (NMR) structure-like basin and showed similar distributions of long-range order parameters (Fig. 7) . Figure 6H superposes the WT NMR structure on the lower populated E211D generated structure with H1 spanning 145-150. Overall, this large-scale motion propensity of H1 relative to H2-H3 along with the reduced H1 helical content can account for the observed cleavage around position 150 in E211D. It is important to note that, for the E211D mutation, no significant effect of the residue (methionine or valine) at position 129 was detected as seen in Figure 7 and in the populations of R208-D211 and E146-D211 salt-bridges (data not shown).
To assess whether E211D/Q distinct PrP res conformers are able to convert WT PrP with a methionine or a valine at codon 129 and to maintain their particular western blot profiles, we exploited protein misfolding cyclic amplification (PMCA) (20) . PMCA is a cell-free assay mimicking the prion replication process that is based on a nucleation model. This method involves cycles of sonication and incubation and generates the amplification of PrP res molecules in a manner conceptually analogous to the polymerase chain reaction (PCR) (21) . The nuclei of conversion are multiplied by the application of ultrasound waves enhancing PrP conversion in the following incubation period. Repeating such cycles leads to the detection of minute amounts of PrP res and also generates new infectious prion particles (22) . This technology has emerged as a useful tool to study prion strain behaviors such as genotypic barrier of transmission and strain mutation/adaptation (23 -26) . We first validated our PMCA procedure by reproducing published data using human isolates as seeds. In our hands and as expected (23, 24, 27) , we observed that PrP res type 2B from patients with variant CJD was amplified using normal brain homogenates from transgenic mice expressing methionine 129 human PrP and from methionine homozygous subjects as substrates, while substrates from other genotypes at codon 129 were not effective. PrP res type 2A from patients with sporadic CJD and a Val-Val or Met-Val genotype at codon 129 can be amplified using normal brains from transgenic mice expressing valine 129 human PrP as a substrate (Supplementary Material, Fig. S1 ). We next studied the behaviors E211D/Q PrP res during PMCA procedures. As shown in Figure 8A , one round of PMCA was sufficient to consistently amplify not only fulllength PrP res but also the C-terminal cleaved fragment ( Fig. 8A -C) . This pattern of PMCA was observed using both types of substrates (with a methionine or a valine at codon 129). However, when serial rounds of PMCA were performed, PrP res amplification was not maintained along to iterative dilutions necessary to refresh the substrate at each round, suggesting that the PrP res produced by PMCA is less effective in converting PrP C than the in vivo generated PrP res (Fig. 8D ). When PrP res from E211Q patient was analyzed, no C-terminal cleaved fragment of PrP res was detected nor amplified ( Fig. 8A -B) .
DISCUSSION
Distinct point mutations leading to distinct phenotypes are a well-known phenomenon in inherited prion and other neurodegenerative disorders. The E211D mutation is responsible for a glutamic acid to aspartic acid substitution at residue 211 of PrP. This mutation has never been identified in our series of 7494 studied chromosomes from French individuals including 1458 chromosomes from patients with possible, probable or definite prion diseases (including sporadic, iatrogenic, variant CJD and 280 cases of inherited CJD, FFI and GSS) or in other published studies of Caucasian, Japanese and Korean individuals (28 -30) . Other features that support a direct association between substitutions at codon 211 and the prion diseases reported here are (i) the finding that this mutation was present in members of four prion disease-affected Congo red stain, (C) PAS stain, (D) thioflavine S stain and (E and F) tau immunohistochemistry using the AT8 antibody in the middle frontal gyrus of the patient showed positive neurites around amyloid plaques and numerous tau-positive neurofibrillary tangles that appear in brown. In (G) and (H), Bodian silver impregnation showed neuritic multicentric plaques and neurofibrillary tangles (filamentous argyrophilic inclusions in the cytoplasm of neurons that appears in dark brown). Scale bars: 80 mm. To our knowledge, this is the first report showing that two amino acid changes affecting the same residue are responsible for distinct neurodegenerative disorders with different clinical, neuropathological and biochemical features. The discovery of such a mechanism in the prion field underlines the central role of the prion protein structural dynamics in the pathogenic process. Missense variants at codon 232 of PRNP have been associated with either sporadic-like MCJ (M232R, predominantly in eastern Asia) or GSS (M232T, one family from Poland has been reported) (34, 35) . However, the pathogenicity of the M232R variant has been recently challenged notably because of its presence in healthy or non-CJD individuals at a frequency incompatible with a causal role in prion disease, suggesting that it could be an uncommon polymorphism (36) . Interestingly, a mechanism similar to that observed with PRNP mutations at residue 211 has been evidenced in corneal dystrophies associated with TGFBI gene mutations (37, 38) . In these rare diseases, a hot spot of the mutation has been identified at residue 124 of keratoepithelin, the product of TGFBI, leading to various clinical and pathological patterns of dystrophies, with various deposits in cornea (designed as lattice, Avellino or Reis Buckler's type). Moreover, one of the mutations involved in such disease has been associated with amyloidogenic intermediates. Beyond the prion phenomenon, these combined observations in diseases affecting different tissues support the view that specific residues play a pivotal role in the phenotypic expression of inherited human proteinopathies.
Substitutions at residue 211 of the prion protein also deeply impact the biochemical properties of abnormal PrP that and constitutes a hallmark of structural differences in abnormal PrP assemblies.
According to the fact that the E211 residue is located in H3 and is involved in a salt bridge with R208, any mutation of this residue should therefore affect the PrP structural dynamic. Indeed, as shown in Figure 4 even if the overall secondary structure does not change, both the internal dynamics and the aggregation pathway appear to be modified when either Q or D replaced E211. When E211Q PrP structural dynamics is quasi similar to WT PrP, E211D substitution promoted the 
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formation of a salt bridge between R208 of the third a-helix (H3) and E146 of the first a-helix (H1). The consequence of this last modification is a decrease in H1 content and modification of motion propensity of H1 relative to the H2 -H3 subdomain. The modification of the internal motion leads to a perturbation of the folding pathway and therefore of the aggregation process as it has been already reported for artificial PrP mutants (19, 39) . As shown by DSC thermograms and SEC experiments, E211Q also affects slightly the folding pathway and increases the aggregation propensity even if its consequence on the PrP structural dynamics is moderate. All these observations suggest that H3 region and specifically residue 211 play an important role in the PrP folding pathway through the modulation of PrP internal dynamics. Altogether, the presence of a C-terminal truncated fragment of PrP res and the results of MD of PrP, showing that the E211D mutation induces H1 destabilization, suggest the formation of a PrP res conformer with an unstable subdomain around amino acid 150 that seems to be maintained during the PrP conversion process. In order to evidence such a molecular species and to assess its ability to convert WT human PrP, we took the advantage of the cell-free PMCA system. One round of PMCA was sufficient to amplify not only full-length PrP res but also the C-terminal cleaved fragment using the E211D PrP res as a seed. Our findings suggest that E211D-PrP res is able to convert WT human PrP C into a molecular species that is secondary cleaved during PK digestion in accordance with the PK cleavage sites identified on the prion protein sequence (40) . Thus, we can speculate that the specific PrP res conformation associated with this mutation, characterized by protein instability around residue 150, was dictated in vitro to the WT PrP. The C-terminal cleaved fragment was not consistently maintained during serial rounds of PMCA, suggesting that E211D-like conformers produced by PMCA have a reduced capacity to convert PrP C compared with brain-extracted E211D PrP res (Fig. 8D) . PMCA results were independent of the residue 129 of the substrate and, on the contrary, strictly dependent on the mutation at position 211 of the seed since no cleaved fragment was produced by PMCA using E211Q-PrP res . The presence of the 7-kDa-PrP res fragment, as the major amyloid component in the affected brain, may contribute to the phenotypical switch between CJD and GSS that we observed in patients with distinct amino acid substitutions at codon 211. It is consistent with a central role of PrP res conformation in the pathological process including amyloid plaque formation. In this hypothesis, a specific role for the 7 kDa fragment in neurodegeneration is mandatory and 
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clearly supported by in vitro results showing that 82-146 PrP peptides induce a partially PrP-dependent neuronal apoptosis through the formation of oligomeric species into cortical cell cultures, astroglial proliferation and microglial activation (41, 42) . Our results also suggest that, beyond the presence of an amino acid substitution at position 211, the main factor associated with tau pathology such as neurofibrillary tangles is the accumulation of a C-terminal-truncated PrP res fragment. This observation provides a theoretical basis for the design of experimental models to explore tau aggregation and its relationship with protein misfolding and amyloid plaque formation. Exploring inherited forms of prion diseases revealed original and unexpected mechanisms that govern the phenotypegenotype relationship. The new molecular mechanism that we report here, driving a phenotypical switch in patients with the mutation at the same codon of PRNP, is unique among neurodegenerative disorders, strongly supports the prion model and provides new ways to investigate the complex relationship between the PrP sequence, PrP res formation and neurodegenerative patterns including amyloid plaques formation and tau neurofibrillar pathology.
MATERIALS AND METHODS

PRNP study
All patients or their relatives gave a written informed consent for genetic and post mortem studies. Genomic DNA was extracted from peripheral blood leukocytes using a Macherey Nagel kit, according to the manufacturer's instructions. The coding sequence of PRNP (NM_000311) was amplified and sequenced as described (31) . Briefly, primers amplified two different overlapping fragments of the coding sequence of PRNP: forward: 5 ′ -ATGCTGGTTCTCTTTGTG-3 ′ and reverse:
′ and reverse 5 ′ -CTCCCTCAAGCTGG AAAAAGA-3 ′ . Amplification reactions were carried out in a total volume of 50 L containing 100 ng of genomic DNA. PCR products were directly sequenced on both strands with the Big dye terminator kit (Applied Biosystems) according to the manufacturer's instructions using the previously described primers.
Neuropathological study
Areas of interest were sampled from 1 cm thick coronal sections of formalin-fixed hemisphere as described (43) . Seven micron-thick sections were stained with hematoxylin and eosin, periodic acid-Schiff, Congo red and Bodian silver impregnation coupled to luxol fast blue. Thioflavine-S staining (Sigma) was performed as previously described (44) and observed using a Zeiss Axiovert 200 M microscope equipped with a Coolsnap HQ CDD camera. PrP immunohistochemistry was performed using the 12F10 mouse monoclonal antibody (IgG2a kappa, 1:200 dilution; Spibio, France) directed against amino acid residues 144-152 of human PrP with 
Biochemical analysis of PrP res
Frozen tissues were stored at 2808C. The brains were homogenized at 20% (w/v) using a Ribolyser (Bio-Rad Laboratories) in 5% sterile glucose. One volume of a 20% NaCl solution and one volume of a detergent solution (20% sarkosyl, 2% SB3-14 and Tris HCl 20 mM, pH 7.4) were added to one volume of 20% brain homogenate. This mixture had a final pH of 7.6 and was digested with proteinase K at 10 mg/ ml (diluted in Tris -HCl 50 mM, pH 8, CaCl 2 1 mM) for 1 h at 378C. PrP res was then purified by centrifugation at 27 500 g for 2 h at room temperature on 20% sucrose cushion as described previously (45) . When deglycosylation was necessary, protein extracts were incubated with peptide endopeptidase F (PNGase F, New England Biolabs, Evry, France) according to the manufacturer's instructions. Samples were subjected to a 12% Tris-glycine sodium dodecyl sulfate -polyacrylamide gel electrophoresis. Proteins were electroblotted onto the nitrocellulose membrane. PrP staining was performed using anti-PrP monoclonal antibody 3F4 (IgG2a, epitope 109 -112 of the human PrP sequence), SAF60 (IgG2b kappa, epitope 157 -161 of the human PrP sequence), 12B2 (IgG1, epitope 89-93 of the human PrP sequence) or 1E4 (IgG1, epitope 97-108 of the human PrP sequence) and revealed using chemiluminescence (ECL; RPN-2209; Amersham Biosciences, Freiburg, Germany).
Protein expression and biophysical characterization
E211Q and E211D mutations were performed on Met129 WT human PrP scaffold and cloned on pet 22b vector for expression in Escherichia coli BL21 strain according to the previous protocol (46) . CD spectra were recorder with a JASCO 810 polarimeter at 158C, 50 mM protein concentration in 10 mM 2-(N-morpholino)ethanesulfonic acid buffer, pH 6.5. DSC measurements were performed with VpDSC from mCal. The thermograms for all proteins were recorded at 18C/min in 20 mM sodium citrate buffer, pH 4.1 (18) . The SEC experiments were performed using TSK 4000SW column with sodium citrate 20 mM, pH 4, as a running buffer. The oligomerization kinetics were performed as previously described by heating 80 mM of protein at 508C (19) .
Molecular modeling of PrP
The recombinant PrP structure is characterized by a flexible, unstructured N-terminal tail (amino acids 1 -124) and a globular C-terminal domain of three a-helices [H1 (144 -153), H2 (172 -192) and H3 (200 -225)] and a small anti-parallel b-sheet: S1(129 -130) and S2(162 -163). Here, the starting point for all MDs, shown in Supplementary Material, Figure S2 , is the human NMR C-terminal structure (33) with PDB entry 1QLX. All variants were constructed using in-house programs. MD simulations were performed at pH 7 with the GROMACS program by using gromos96 force field, simple point charge-extended water model and periodic boundary conditions (47) . MD used the Part Mesh Ewald method with a grid size of 1.2 Å for electrostatic interactions and cutoff distances of 14 Å for Van der Waals interactions. MD was performed in the isothermal-isobaric ensemble at constant temperature (310 K) and pressure (1 atm); a weak coupling to external heat and pressure bath was applied with relaxation time of 0.1 and 0.5 ps, respectively. The integration time-step was set to 0.002 ps with bond lengths constrained by the linear constraint solver algorithm, and the coordinates were saved every 0.5 ps. Both WT and E211D/M129 were subjected to one MD trajectory of 100 ns, while both E211D/V129 and E211Q were subjected to two MD trajectories of 30 ns using different initial velocities. Prior to analysis, each system was equilibrated during 1 ns, and all analyses reported here use the first 30 ns of the production. The results do not change by considering the full 100 ns trajectory for WT and E211D/M129, indicating that the MD sampling has reached convergence within 30 ns. The simulation convergence for both E211D/V129 and E211Q is also illustrated by the reproducibility of the results using two trajectories of 30 ns.
Following our previous PrP simulation study (48) , the C-terminal domain was decomposed into the S1-H1 -H2 subdomain (residues 125-171) and the subdomain H2-H3 (residues 172-228). Thermal motions were analyzed by using Ca-RMSD fluctuations from the MD average structure, secondary structure composition and free energy projections using several order parameters including the Ca-RMSD deviation from the NMR WT structure, the angle between helix H1 and subdomain H2 -H3 (Supplementary Material, Fig. S2 ) and the number of native inter-subdomain contacts between helix H1 and subdomain H2 -H3. Free energy projections were calculated from the histogram distribution of the populations by applying the Boltzmann equation.
Protein misfolding cyclic amplification
PMCA reaction was set up as described by Castilla et al. (22) . Normal brains from transgenic mice overexpressing human PrP on a murine PrP knock-out background were used to amplify PrP res . The tg152 mice overexpress human PrP with a valine at codon 129 (designated HuTgVal afterward) (49), while tg650 mice overexpress human PrP with a methionine at codon 129 (designated HuTgMet afterward) (44) . Normal and prion-infected brain homogenates were prepared at 10% concentration in conversion buffer (phosphate-buffered saline with 0.15 M NaCl, 1% Triton X-100, 0.005% ethylenediaminetetraacetic acid, pH 8, and complete protease inhibitor cocktail Roche 1×) and designated as a 'substrate' and a 'seed', respectively. In serial PMCA, one volume of a fresh substrate was added to one volume of the PMCA reaction before each following round. Preparations were loaded onto 0.2-ml PCR tubes and positioned on a Misonix tube holder.
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A fraction of each mixture was removed and immediately subjected to PK digestion in another tube. The remaining volume was then subjected to PMCA using a Misonix S4000 sonicator (Misonix, Farmingdale, NY, USA) programmed to perform 120 cycles of 30 s pulse of sonication set at 145 W potency followed by incubation in the water of the sonicator bath. Samples were digested with PK (Eurobio) at 378C for 60 min under agitation. Negative controls (normal brain homogenate) were included in each experiment to ensure that PK digestion of PrP C is complete. Digested samples were mixed with Laemmli buffer and heated to 1008C for 5 min. A 10 ml volume of each final mixture was loaded onto precast Invitrogen Bis -Tris gels and electroblotted into nitrocellulose membrane. Proteins were labeled using the anti-PrP 3F4 mAb and visualized using ECL chemiluminescence (GE Amersham). Densitometric analysis was performed by using a GS-800 densitometer and its dedicated Quantity One software (Bio-Rad Laboratories). The amplification factor was determined (PMCA+/PMCA2) as described elsewhere (26) and data were statistically examined by one-way analysis of variance as previously performed by Saa et al. (50) .
